Resolution Therapeutics advanced its regenerative macrophage cell therapy strategy this week, with multiple updates centered on its Phase I/II EMERALD trial in end-stage liver disease. The company reiterated the high unmet need in chronic liver failure, where mortality is high and many patients are ineligible for liver transplantation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CEO Amir Hefni highlighted in a BiotechTV interview that the EMERALD interim analysis cohort has been fully recruited, with active enrollment continuing across 15 sites in the U.K. and Spain. Resolution is targeting an interim data readout toward the end of Q3 2026, providing clearer visibility on upcoming clinical milestones.
The EMERALD study, evaluating lead candidate RTX001, is being conducted across eight NHS hospitals in the U.K. and seven sites in Spain, underscoring a broad early clinical footprint. Investigators at Royal Liverpool University Hospital and Glasgow Royal Infirmary have emphasized the severe disease burden and the need for alternatives or complements to transplantation.
RTX001 and the EMERALD program received the “Best Therapeutic R&D Programme of the Year” award at the 2026 One Nucleus Awards, adding sector recognition ahead of key data. While the award does not change clinical risk, it may modestly enhance Resolution’s visibility with potential partners and investors.
The company also gained scientific and policy exposure through a BioCentury feature on fibrosis and a Drug Discovery World podcast, where Hefni outlined how regenerative macrophage therapy aims to address the root causes of fibrosis. In parallel, U.K. health policymakers, including the Secretary of State for Health and Social Care, were briefed on Resolution’s technology at Edinburgh BioQuarter.
At the Advanced Therapies conference in London, Resolution showcased capabilities in CMC, AI- and automation-enabled cell therapy manufacturing, and supply chain logistics, indicating early planning for scalability. Collectively, the week’s developments signal solid clinical execution, rising industry recognition, and growing policy engagement as the EMERALD interim readout approaches.